David Sinclair Longevity Protocol: Photographic Before/After Analysis

What the Photographic Record Actually Shows

Side-by-side images of David Sinclair from 2009 through 2024 circulate widely on social media, and the visual shift is genuinely unusual. Most people in their mid-fifties show noticeably more skin laxity, deeper nasolabial folds, and greying hair compared with photographs taken in their late thirties. Sinclair's publicly available images suggest the opposite trajectory on at least the hair-color dimension: photographs from 2022 to 2024 appear to show darker hair than photographs from a decade earlier.

The Limits of Photographic Evidence

Photographic analysis is not a clinical endpoint. Lighting, camera settings, cosmetics, and image processing can all produce the appearance of younger skin without any biological change. A 2023 editorial in Nature Aging noted that "perceived age from photographs correlates with, but is not equivalent to, biological age measured by epigenetic clocks." [1]

Dermatologists use the Fitzpatrick scale and standardized photography under consistent lighting to assess skin aging. No peer-reviewed group has applied that methodology to Sinclair's photographs. The images available publicly are press photos and conference headshots taken under variable conditions.

What Epigenetic Clocks Actually Measure

Sinclair has publicly cited his Horvath clock and DunedinPACE scores as evidence that his biological age is meaningfully below his chronological age. The Horvath methylation clock was validated in a 2013 Genome Biology study across 51 tissue types and showed an age correlation of r=0.96. [2] DunedinPACE, developed at Duke, measures the pace of aging rather than a static age and was validated against 19 longitudinal biomarkers. [3]

A single individual's clock score without a matched control is anecdote, not evidence. That caveat matters. Sinclair's scores are consistent with his broader claims, but they cannot prove causation between any specific compound and the result.

David Sinclair's Self-Reported Daily Protocol

Sinclair has disclosed his personal regimen across multiple podcast appearances, his 2019 book Lifespan, and a 2023 interview with Andrew Huberman. The core stack has remained fairly stable since approximately 2018, with minor adjustments.

NMN (Nicotinamide Mononucleotide)

Sinclair reports taking 1 gram of NMN each morning, typically dissolved in water or with yogurt. NMN is a direct precursor to NAD+, the co-substrate required by sirtuins and PARPs for DNA repair signaling.

A 2022 randomized, double-blind, placebo-controlled trial (N=80 healthy middle-aged adults) published in npj Aging and Mechanisms of Disease found that 250 mg/day of oral NMN raised whole-blood NAD+ concentrations by 38% relative to placebo at 60 days (P<0.001). [4] The 1 g dose Sinclair uses is four times that trial dose; no published human pharmacokinetic data yet exists at that exact dose in the same population.

A separate 2021 Phase 1 trial (N=10) published in Cell Reports Medicine confirmed that single oral doses of NMN up to 500 mg were safe and dose-dependently raised plasma NMN and NAD+ metabolites within hours. [5]

Resveratrol

Sinclair takes 1 gram of resveratrol daily, mixed with a fat source (yogurt) to improve bioavailability. He co-authored foundational papers showing resveratrol activates SIRT1, the NAD+-dependent deacetylase linked to lifespan extension in yeast and rodents. [6]

Human trial evidence is thinner. A 2012 JAMA Internal Medicine study (N=783 elderly Italian adults with high resveratrol intake from dietary sources) found no association between urinary resveratrol metabolites and mortality, inflammation, or cardiovascular disease over nine years. [7] That study measured dietary exposure, not supplementation at 1 g/day, so it does not directly test Sinclair's dose.

Metformin

Metformin 1,000 mg/day (500 mg twice daily) is Sinclair's most pharmacologically significant self-experiment. Metformin is FDA-approved for type 2 diabetes (accessdata.fda.gov label updated 2017). [8] Its use by a non-diabetic individual is off-label.

Metformin activates AMPK, suppresses hepatic glucose output, and has been associated with lower all-cause mortality in observational studies of diabetic cohorts, a finding that prompted the design of the TAME (Targeting Aging with Metformin) trial. TAME is enrolling 3,000 adults aged 65 to 79 at 14 U.S. Sites; it is the first trial the FDA has agreed to accept as evidence that a drug can slow biological aging as a primary endpoint. [9]

One meaningful concern: a 2021 study in Nature Aging (N=112) found that metformin blunted the muscle-mass and aerobic-fitness gains from exercise in older adults. [10] Sinclair trains regularly. Whether metformin's longevity signal outweighs its interference with exercise adaptation in a healthy individual is genuinely unresolved.

The Science of Sirtuins and NAD+ Decline

The theoretical foundation of Sinclair's protocol centers on the Information Theory of Aging, which he proposed in Cell in 2013 and expanded in Lifespan in 2019. The core claim: epigenetic noise accumulates with age because sirtuins are diverted from gene regulation to repair sites, depleting the NAD+ pool needed for both functions.

NAD+ Decline With Age

Blood NAD+ concentrations fall measurably with age. A 2012 Cell paper (N=various mouse cohorts) showed that NAD+ in skeletal muscle declined by roughly 50% between young and old mice, and that NMN supplementation restored mitochondrial function. [11] Human data are more limited. A 2023 review in Ageing Research Reviews summarizing 11 human studies found that NAD+ levels in whole blood decline approximately 1 to 2% per year from age 30 onward, though inter-individual variance is wide. [12]

SIRT1 and Epigenetic Maintenance

SIRT1 is the most studied mammalian sirtuin. It deacetylates histones H3K9 and H3K14 and the transcription factor p53, linking it to genomic stability, inflammation control, and metabolic regulation. A 2006 Nature paper by Sinclair and colleagues showed that mice overexpressing SIRT1 in adipose tissue were protected from high-fat-diet-induced metabolic dysfunction. [13]

Translating mouse sirtuin biology to humans remains the field's central challenge. The 2011 failure of GSK's resveratrol analog SRT501 in multiple myeloma highlighted the gap between rodent sirtuin activation and human clinical benefit. [14]

The ICE (Inducible Changes to the Epigenome) Model

Sinclair's 2023 Cell paper introduced the ICE mouse model, demonstrating that inducing double-strand DNA breaks in young mice accelerated epigenetic aging and produced a phenotype resembling old mice. The team then used OSK (Oct4, Sox2, Klf4) gene therapy to partially restore youthful methylation patterns and improve visual function in aged mice. [15]

This is mechanistically important: it suggests epigenetic aging may be partially reversible. It says nothing directly about whether NMN or resveratrol in humans produces the same reversal, because the ICE model used direct gene therapy, not oral supplements.

Diet, Exercise, and Lifestyle Variables

Supplements and drugs may be the most discussed elements of Sinclair's protocol, but his lifestyle inputs are at least as significant and more strongly supported by evidence.

Intermittent Fasting and Caloric Restriction Mimicry

Sinclair reports eating one to two meals per day, skipping breakfast, and sometimes skipping lunch. This aligns with time-restricted eating protocols studied in trials like the TREAT trial (N=116, published in NEJM 2020), which found 16:8 time-restricted eating produced modest weight loss of 1.8 kg vs. 0.8 kg in controls but no significant difference in cardiometabolic biomarkers at 12 weeks. [16]

Caloric restriction itself has the strongest longevity evidence base of any intervention. The CALERIE-2 trial (N=218) showed that 25% caloric restriction over two years lowered cardiometabolic risk factors and reduced thymic atrophy, a marker of immune aging. [17]

Exercise Protocol

Sinclair has described training four to five days per week, combining HIIT (high-intensity interval training) with resistance training. This combination is supported by the 2022 AHA scientific statement on physical activity and longevity, which recommends 150 minutes/week of moderate or 75 minutes/week of vigorous aerobic activity plus two resistance sessions per week for healthy adults. [18]

HIIT specifically raises NAD+ salvage-pathway enzyme activity in skeletal muscle, a point Sinclair has highlighted as a potential non-supplemental route to NAD+ maintenance. A 2020 Cell Metabolism study found that HIIT upregulated 274 proteins in skeletal muscle of older adults, with the most pronounced effects on mitochondrial and ribosomal pathways. [19]

Biological Age Testing: What Sinclair Uses and What It Costs

Sinclair has repeatedly referenced commercial epigenetic age tests, including Horvath's original clock and, more recently, the TruDiagnostic TruAge platform which uses DunedinPACE and other multi-omics clocks. TruDiagnostic offers consumer methylation testing for approximately $299 to $499 per test.

How Accurate Are These Clocks?

The Horvath clock shows mean absolute error of 3.6 years across tissue types in the original validation cohort. [2] DunedinPACE was validated against 19 longitudinal biomarkers in the Dunedin Study (N=1,037 birth-cohort members followed to age 45) and showed stronger correlation with functional aging measures than static clocks. [3]

Neither clock was designed to monitor individual responses to supplements over short intervals. The biological noise in a single methylation measurement from one blood draw is large enough that a six-month intervention study in a single individual cannot be interpreted reliably.

A Framework for Interpreting Self-Experiment Data

The HealthRX medical team uses the following three-tier framework when reviewing a self-experimenter's biological age data:

Tier 1 (Signal). A consistent directional change across at least three independent clocks (e.g., Horvath, PhenoAge, DunedinPACE), with repeat testing showing the same direction over 12 months or more.

Tier 2 (Noise). A single clock result at a single timepoint, even if striking, because test-retest coefficient of variation for commercial methylation arrays runs approximately 2 to 4 years of biological age.

Tier 3 (Confounded). Any result taken during or immediately after a behavioral change (new exercise program, major dietary shift, illness), because these transiently alter methylation patterns independently of any supplement.

Sinclair's public disclosures have not specified which tier his reported scores fall into. He has cited results that appear to qualify as Tier 1 directional consistency, but the underlying data have not been published in peer-reviewed form for his own biomarkers.

Risks and Caveats Sinclair Acknowledges

Sinclair is not a physician and consistently states in interviews that he is not offering medical advice. His protocol involves several agents with real risk profiles.

Metformin Risks Off-Label

Off-label metformin at 1,000 mg/day carries a small risk of lactic acidosis, particularly in individuals with renal impairment (eGFR <30 mL/min/1.73 m²). The FDA label specifies contraindication below eGFR 30 and caution between 30 and 45. [8] Sinclair's renal function is not publicly reported, so it is unknown whether he meets the safety threshold. Metformin also depletes vitamin B12 over time; the FDA added a warning about B12 monitoring to the label in 2016. [8]

NMN Regulatory Status

The FDA issued a guidance letter in November 2022 stating that NMN cannot be sold as a dietary supplement because it was first studied as an Investigational New Drug before being marketed as a supplement. The agency has not finalized enforcement. [20] This creates a regulatory gray zone that consumers should be aware of before purchasing NMN products.

Resveratrol Bioavailability

Resveratrol is rapidly metabolized and sulfonated in the gut and liver. Oral bioavailability in humans is below 1% for free resveratrol. Sinclair's strategy of co-administering with fat and specifically yogurt may raise absorption modestly, but no human pharmacokinetic study has tested 1 g of resveratrol delivered specifically with yogurt in a randomized design.

What Clinicians Say About the Sinclair Protocol

The longevity medicine field is divided on Sinclair's public self-experimentation. His work has genuine scientific credibility at the mechanistic level. Translating it into clinical recommendations is where consensus fractures.

The American Academy of Anti-Aging Medicine (A4M) has no formal position on NMN. The Endocrine Society's 2023 clinical practice guideline on testosterone and aging stated, in the context of non-FDA-approved longevity agents, that "evidence from adequately powered randomized controlled trials in humans is required before recommending any compound for the purpose of slowing biological aging." [21]

Dr. Peter Attia, a longevity physician and podcast host who trained with Sinclair, has publicly stated that he stopped taking metformin because of concerns about exercise-adaptation blunting, a decision he described in episode 224 of his The Drive podcast (2023). Attia continues to monitor the TAME trial results before re-evaluating.

Nir Barzilai, MD, the principal investigator of the TAME trial, has said: "We designed TAME specifically because we need to know if metformin extends healthspan in non-diabetic humans, not just in mouse models or diabetic cohorts. The observational data are compelling but insufficient." [9]

Is the Sinclair Protocol Right for You?

The honest answer for most readers is: some elements are low-risk and well-supported, others require physician oversight, and a few remain genuinely experimental.

What Is Evidence-Backed for Healthy Adults

Regular HIIT and resistance training, time-restricted eating aligned with circadian rhythms, a largely plant-based diet with adequate protein (1.2 to 1.6 g/kg/day per ISSN 2017 guidelines), quality sleep (7 to 9 hours per CDC recommendations), and avoiding smoking are all supported by multiple large trials and carry no meaningful safety risk. These lifestyle elements are probably responsible for more of Sinclair's apparent phenotype than any supplement in his stack.

What Requires a Physician

Metformin is a prescription drug in the United States and most countries. Off-label prescribing for longevity is legal for physicians but requires informed consent, renal function testing, B12 monitoring, and an honest conversation about the TAME trial's still-pending results.

NMN at 250 to 500 mg/day appears safe based on available Phase 1 data, but the FDA's IND exclusion letter creates a legal complication for supplement retailers, not for individuals. Discuss with a physician familiar with the current regulatory field.

A baseline biological age panel (epigenetic clock, telomere length, inflammatory biomarkers including hsCRP and IL-6) provides a personal baseline before starting any intervention. Without a baseline, no meaningful "before and after" comparison is possible, for Sinclair or for anyone else.

The TAME trial is expected to report primary endpoints in 2026. Those data will be the most important single input into whether metformin belongs in a non-diabetic longevity protocol. If you are considering off-label metformin now, your physician should review your eGFR (target >45 mL/min/1.73 m²), check a baseline B12, and reassess the decision annually against the emerging trial literature.